Registry for patients with pediatric atopic dermatitis receiving systemic treatments

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The Registry for Systemic Eczema Therapies (RESET) is a comprehensive database and biospecimen repository aimed at patients with pediatric-onset atopic dermatitis (AD) who are using or planning to use systemic treatments. This registry will facilitate efficient recruitment for research studies and enable timely notifications about new FDA-approved therapies for AD. It will collect data to compare treatment effectiveness and monitor safety profiles of both traditional and novel systemic agents. Additionally, it aims to identify patients with moderate-to-severe AD who may benefit from emerging therapies.

Why it matters

Who can join: the full rules

Inclusion criteria:

* Age \<26 years old
* Current physician diagnosis of atopic dermatitis
* Provide signed informed consent if ≥ 18 years old
* Provide signed informed consent by parent or legal guardian (if \<18 years old) and informed assent if applicable
* Subject and/or parent/legal guardian is willing to be contacted in the future by study staff
* Seen for clinical care at Johns Hopkins since 1/1/2017
* Previously on, currently on, or planning to initiate (within next 6 months) a systemic AD therapy

Exclusion criteria:

* Age ≥26 years old at the time of registry enrollment
* Does not speak English
* If \<18 years old, has a primary caretaker who does not speak English
* If \<18 years old, parent/legal guardian is unwilling to sign the written informed consent
* Is a foster child
* Has not received clinical care at Johns Hopkins since 1/1/2017

Where it's running

• Johns Hopkins University
  Baltimore, Maryland, United States Recruiting

Study contacts

• Principal investigator: Joy Wan, MD MSCE — Johns Hopkins University
• Study coordinator: Zeena Mestari, BA
• Email: zmestar1@jh.edu
• Phone: 1 (848) 702-4101‬

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Roflumilast Cream 0.3% for moderate to severe atopic dermatitis in children, adolescents, and adults

  A cream called roflumilast 0.3% is tested once daily to see if it helps people with moderate to severe atopic dermatitis, compared to a non-medicated cream, across ages 6 and up.

  Recruiting at 4 sites Phase 3 Arcutis Biotherapeutics, Inc. · Birmingham, Alabama and 3 other locations · NCT07916480

• Nocturnal ScratchSense ring: test of automatic scratch detection in adults with itchy skin

  This study tests whether the Replior ScratchSense ring can accurately detect and measure nighttime scratching in adults with itchy skin conditions.

  Recruiting Replior AB · Grenoble · NCT07909967

• ADBest TREAT Registry for adults with atopic dermatitis

  A registry in Germany is collecting real-world data from adults with atopic dermatitis to see how treatments are used and how the disease affects quality of life.

  Recruiting Universitätsklinikum Hamburg-Eppendorf · Hamburg · NCT07904546

• How lebrikizumab affects the skin microbiome and mycobiome in adults with atopic dermatitis

  This study looks at whether lebrikizumab changes the skin bacteria, fungi, and specifically Staphylococcus species, in adults with moderate-to-severe atopic dermatitis.

  Recruiting University Hospital Bispebjerg and Frederiksberg · Copenhagen · NCT07807228

• QX-4533 safety study in healthy volunteers and people with moderate-to-severe atopic dermatitis

  This study tests the safety and tolerability of QX-4533, given as a pill, in healthy adults and in patients with moderate-to-severe atopic dermatitis to see how the drug behaves in the body and what side effects may occur.

  Recruiting Phase 1 QuantX Biosciences US Inc. · Shanghai, Shanghai Municipality · NCT07800104

• Tilrekimig for moderate-to-severe eczema in teens and adults

  A 52-week study will test tilrekimig against dupilumab and a placebo to see if it helps people 12 and older with moderate-to-severe atopic dermatitis.

  Recruiting at 31 sites Phase 3 Pfizer · Birmingham, Alabama and 49 other locations · NCT07783425

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.